Millard FE - Search Results

1

Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.

Milowsky MI, Dittrich C, Durán I, Jagdev S, Millard FE, Sweeney CJ, Bajorin D, Cerbone L, Quinn DI, Stadler WM, Rosenberg JE, Lochheed M, Sen P, Squires M, Shi M, Sternberg CN. Milowsky MI, et al. Among authors: millard fe. Eur J Cancer. 2014 Dec;50(18):3145-52. doi: 10.1016/j.ejca.2014.10.013. Epub 2014 Oct 30. Eur J Cancer. 2014. PMID: 25457633 Clinical Trial.

2

Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.

Rosenberg JE, Halabi S, Sanford BL, Himelstein AL, Atkins JN, Hohl RJ, Millard F, Bajorin DF, Small EJ; Cancer and Leukemia Group B. Rosenberg JE, et al. Ann Oncol. 2008 May;19(5):946-50. doi: 10.1093/annonc/mdm600. Epub 2008 Feb 13. Ann Oncol. 2008. PMID: 18272914 Free PMC article. Clinical Trial.

3

The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).

Aggarwal R, Halabi S, Kelly WK, George D, Mahoney JF, Millard F, Stadler WM, Morris MJ, Kantoff P, Monk JP, Carducci M, Small EJ; Alliance for Clinical Trials in Oncology. Aggarwal R, et al. Cancer. 2013 Oct 15;119(20):3636-43. doi: 10.1002/cncr.28285. Epub 2013 Jul 31. Cancer. 2013. PMID: 23913744 Free PMC article. Clinical Trial.

4

Update on chemotherapy in the treatment of urothelial carcinoma.

Costantini C, Millard F. Costantini C, et al. ScientificWorldJournal. 2011;11:1981-94. doi: 10.1100/2011/590175. Epub 2011 Oct 26. ScientificWorldJournal. 2011. PMID: 22125450 Free PMC article. Review.

5

Cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) for advanced-stage Hodgkin's disease: CALGB 8856.

Lester EP, Petroni GR, Barcos M, Johnson JL, Millard FE, Cooper MR, Omura GA, Frei E 3rd, Peterson BA. Lester EP, et al. Among authors: millard fe. Cancer Invest. 2001;19(5):447-58. doi: 10.1081/cnv-100103843. Cancer Invest. 2001. PMID: 11458812 Clinical Trial.

6

Does timing of cytoreductive nephrectomy impact patient survival with metastatic renal cell carcinoma in the tyrosine kinase inhibitor era? A multi-institutional study.

Stroup SP, Raheem OA, Palazzi KL, Liss MA, Mehrazin R, Kopp RP, Patel N, Cohen SA, Park SK, Patterson AL, Kane CJ, Millard F, Derweesh IH. Stroup SP, et al. Urology. 2013 Apr;81(4):805-11. doi: 10.1016/j.urology.2012.10.054. Epub 2013 Feb 13. Urology. 2013. PMID: 23414694

7

Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762).

Lichtman SM, Hollis D, Miller AA, Rosner GL, Rhoades CA, Lester EP, Millard F, Byrd J, Cullinan SA, Rosen DM, Parise RA, Ratain MJ, Egorin MJ; Cancer and Leukemia Group B (CALGB 9762). Lichtman SM, et al. J Clin Oncol. 2006 Apr 20;24(12):1846-51. doi: 10.1200/JCO.2005.03.9289. Epub 2006 Mar 27. J Clin Oncol. 2006. PMID: 16567769 Clinical Trial.

8

Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery.

Silberstein JL, Millard F, Mehrazin R, Kopp R, Bazzi W, DiBlasio CJ, Patterson AL, Downs TM, Yunus F, Kane CJ, Derweesh IH. Silberstein JL, et al. BJU Int. 2010 Nov;106(9):1270-6. doi: 10.1111/j.1464-410X.2010.09357.x. BJU Int. 2010. PMID: 20394613

9

Does timing of targeted therapy for metastatic renal cell carcinoma impact treatment toxicity and surgical complications? A comparison of primary and adjuvant approaches.

Patel N, Woo J, Liss MA, Palazzi KL, Randall JM, Mehrazin R, Jabaj R, Mirheydar HS, Gillis K, Lee HJ, Patterson AL, Kane CJ, Millard F, Derweesh IH. Patel N, et al. Can J Urol. 2016 Apr;23(2):8227-33. Can J Urol. 2016. PMID: 27085828 Clinical Trial.

10

Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.

Kindler HL, Millard F, Herndon JE 2nd, Vogelzang NJ, Suzuki Y, Green MR. Kindler HL, et al. Lung Cancer. 2001 Feb-Mar;31(2-3):311-7. doi: 10.1016/s0169-5002(00)00166-5. Lung Cancer. 2001. PMID: 11165412 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

42 results

Search Page

Filters